Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson’s Disease
Explore this paper's citation graph
Summary
The concept of using trehalose as a novel therapeutic strategy that might prevent/reverse α-synuclein aggregation for the treatment of Parkinson’s disease is supported.
- Type
- article
- Published
- 2016-05-01
- Cited by
- 125
- References
- 41
- OpenAlex
- https://openalex.org/W307046337
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:17132986
Keywords
Neurochemical, Parkinson's disease, Trehalose, Neurodegeneration, Dopaminergic
References
- Molecular Pathways of Neurodegeneration in Parkinson's Disease
- Acute administration of fluoxetine normalizes rapid eye movement sleep abnormality, but not depressive behaviors in olfactory bulbectomized rats
- LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing
- Effect of Trehalose on PC12 Cells Overexpressing Wild-Type or A53T Mutant α-synuclein
- Small molecules enhance autophagy and reduce toxicity in Huntington’s disease models
- Dynamic Changes in Presynaptic and Axonal Transport Proteins Combined with Striatal Neuroinflammation Precede Dopaminergic Neuronal Loss in a Rat Model of AAV α-Synucleinopathy
- Potential therapeutic applications of autophagy
- Orexin A promotes histamine, but not norepinephrine or serotonin, release in frontal cortex of mice
- Metal-catalyzed oxidation of alpha-synuclein: helping to define the relationship between oligomers, protofibrils, and filaments.
- Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease
- Trehalose: a biophysics approach to modulate the inflammatory response during endotoxic shock.
- Trehalose inhibits fibrillation of A53T mutant alpha-synuclein and disaggregates existing fibrils.
- Trehalose, a Novel mTOR-independent Autophagy Enhancer, Accelerates the Clearance of Mutant Huntingtin and α-Synuclein*
- Trehalose: a review of properties, history of use and human tolerance, and results of multiple safety studies.
- The accumulation of neurotoxic proteins, induced by proteasome inhibition, is reverted by trehalose, an enhancer of autophagy, in human neuroblastoma cells.
- LC3 conjugation system in mammalian autophagy
- Autophagy in Neurodegenerative disorders: Pathogenic Roles and Therapeutic Implications
- Human platelets loaded with trehalose survive freeze-drying.
- Levels of alpha‐synuclein mRNA in sporadic Parkinson disease patients
- Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson's disease mouse model.
Cited by
- Trehalose upregulates progranulin expression in human and mouse models of GRN haploinsufficiency: a novel therapeutic lead to treat frontotemporal dementia
- Autophagy induction as a therapeutic strategy for neurodegenerative diseases.
- The 6-hydroxydopamine model and parkinsonian pathophysiology: Novel findings in an older model.
- Compartment-dependent mitochondrial alterations in experimental ALS, the effects of mitophagy and mitochondriogenesis
- Development of Passive Immunotherapies for Synucleinopathies
- Congenital disorders of autophagy: an emerging novel class of inborn errors of neuro-metabolism.
- Autophagy and Alpha‐Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies
- Triptolide Promotes the Clearance of α-Synuclein by Enhancing Autophagy in Neuronal Cells
- Potential applications of stress solutes from extremophiles in protein folding diseases and healthcare
- ER stress and Parkinson's disease: Pathological inputs that converge into the secretory pathway.
- Natural Compounds Preventing Neurodegenerative Diseases Through Autophagic Activation.
- Resveratrol alleviates MPTP-induced motor impairments and pathological changes by autophagic degradation of α-synuclein via SIRT1-deacetylated LC3
- α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.
- Trehalose does not improve neuronal survival on exposure to alpha-synuclein pre-formed fibrils
- p62 Pathology Model in the Rat Substantia Nigra with Filamentous Inclusions and Progressive Neurodegeneration
- Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease
- Neuroprotective Natural Products for the Treatment of Parkinson's Disease by Targeting the Autophagy–Lysosome Pathway: A Systematic Review
- Autophagy in neuroinflammatory diseases.
- The Role of the Heat Shock Protein B8 (HSPB8) in Motoneuron Diseases
- Animal models of α-synucleinopathy for Parkinson disease drug development
Related papers
- Monitoring Phase Transformations in Intact Tablets of Trehalose by FT-Raman Spectroscopy
- Investigation of the behavioral and neurochemical effects of monosodium glutamate on neonatal rats.
- Voluntary Binge-Patterned Alcohol Drinking and Sex-Specific Influences on Monoamine-Related Neurochemical Signatures in the Mouse Gut and Brain.
- Acute net stressor increases whole-body cortisol levels without altering whole-brain monoamines in zebrafish.
- Monoamines in autism: an update of neurochemical research on a pervasive developmental disorder.
- Heterogeneity of the mechanisms of action of antidepressants
- Rapid changes in monoamine levels following administration of corticotropin-releasing factor or corticosterone are localized in the dorsomedial hypothalamus.